Coronary atherosclerosis
Conditions
Interventions
Intensive lipid-lowering group:On the basis of conventional statin therapy, use Repatha subcutaneous injection to treat 1 vial of Q2W
control group:Atorvastatin 20mg/day or rosuvastatin 10mg/day
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 years and over; 2. Coronary angiography confirmed the presence of borderline coronary lesions in ACS patients; 3. The LDL-C levels on baseline (One of the following conditions can be met): (1) Baseline LDL-C >= 70 mg/dL or non-HDL-C >= 100 mg/dL who have received >= 4 weeks of continuous statin maximum tolerated dose therapy before enrollment; (2) Baseline LDL-C >= 125 mg/dL or non-HDL-C >= 155 mg/dLage before enrollment or not receiving statin therapy continuously; 4)Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Clinical instability (hemodynamic or electrical instability); 2. Uncontrolled arrhythmia, defined as recurrent or symptomatic ventricular tachycardia, drug-uncontrolled atrial fibrillation with rapid ventricular response within three months prior to screening; 3. Severe renal insufficiency (defined as eGRF < 30ml/min/1.73m^2); 4. Active liver disease or liver dysfunction, either documented in the patient's medical record or defined as an increase in AST or ALT greater than 3 times the upper limit of normal; 5. TSH is lower than the lower limit of normal or TSH rises more than 3 times the upper limit of normal; 6. Documented statin or rosuvastatin (any dose) intolerance or other statin intolerance; 7. Known hypersensitivity to contrast media, heparin, aspirin, ticagrelor or clopidogrel; 8. Known allergy to excipients that require the use of the drug; 9. Patients who have been treated with ivolumab or other PCSK9 inhibitors; 10. Received cholesteryl ester transfer protein inhibitor treatment within 12 months before screening; 11. Received systemic steroids or cyclosporine within the past 3 months; 12. Known infection, massive bleeding, metabolic or endocrine disorders judged by the investigator; 13. Patients who have been included in other research studies; 14. Patients with active malignant tumors who need treatment; 15. Pregnant or breastfeeding women; 16. History of myocardial infarction or coronary revascularization; 17. Severely impaired CCTA at baseline or follow-up quality (severe artefacts present, undiagnosed); 18. Patient discontinued treatment during follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of CT-FFR values 20mm away from patients with coronary vascular borderline lesions; | — |
Secondary
| Measure | Time frame |
|---|---|
| LDL-C;Changes of CT-FFR values within 20mm away from patients with coronary vascular borderline lesions vessel ends;Major adverse cardiovascular events;Adverse drug reaction events; | — |
Countries
China
Contacts
Public ContactYang Qing
Tianjin Medical University General Hospital
Outcome results
None listed